

HR 4991

Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Aug 10, 2021

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Aug 11, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/4991>

Sponsor

Name: Rep. DeFazio, Peter A. [D-OR-4]

Party: Democratic • **State:** OR • **Chamber:** House

Cosponsors (11 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cohen, Steve [D-TN-9]	D · TN		Aug 10, 2021
Rep. Doggett, Lloyd [D-TX-35]	D · TX		Aug 10, 2021
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Aug 10, 2021
Rep. Kaptur, Marcy [D-OH-9]	D · OH		Aug 10, 2021
Rep. Khanna, Ro [D-CA-17]	D · CA		Aug 10, 2021
Rep. Pocan, Mark [D-WI-2]	D · WI		Aug 10, 2021
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Aug 10, 2021
Rep. Pingree, Chellie [D-ME-1]	D · ME		Aug 27, 2021
Rep. Garcia, Jesus G. "Chuy" [D-IL-4]	D · IL		Sep 7, 2021
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		Sep 20, 2021
Rep. Stansbury, Melanie Ann [D-NM-1]	D · NM		Jul 27, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Aug 11, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2021

This bill requires companies that receive federal funding for research (or a license of the rights to a patent or regulatory test data) for a biomedical product or service to agree to set reasonable prices for the resulting biomedical product or service.

The Department of Health and Human Services (HHS) must determine a reasonable price based on a formula that ensures the U.S. price for the product or service is not more than the median price for the product or service in Canada and six other reference countries with, based on specified criteria, large economies and high incomes.

Companies entering these agreements also must report to HHS certain financial information related to the biomedical product or service involved.

Actions Timeline

- **Aug 11, 2021:** Referred to the Subcommittee on Health.
- **Aug 10, 2021:** Introduced in House
- **Aug 10, 2021:** Referred to the House Committee on Energy and Commerce.